              <GPOTABLE CDEF="s200,8" COLS="2" OPTS="L2">
                <TTITLE>Ratings for Impairment of Visual Fields</TTITLE>
                <BOXHD>
                  <CHED H="1"> </CHED>
                  <CHED H="1">Rating</CHED>
                </BOXHD>
                <ROW>
                  <ENT I="22">6080 Visual field defects:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Homonymous hemianopsia</ENT>
                  <ENT>30</ENT>
                </ROW>
                <ROW>
                  <ENT I="22">Loss of temporal half of visual field:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Bilateral</ENT>
                  <ENT>30</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Unilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Or evaluate each affected eye as 20/70 (6/21)</ENT>
                </ROW>
                <ROW>
                  <ENT I="22">Loss of nasal half of visual field:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Bilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Unilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Or evaluate each affected eye as 20/50 (6/15)</ENT>
                </ROW>
                <ROW>
                  <ENT I="22">Loss of inferior half of visual field:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Bilateral</ENT>
                  <ENT>30</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Unilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Or evaluate each affected eye as 20/70 (6/21)</ENT>
                </ROW>
                <ROW>
                  <ENT I="22">Loss of superior half of visual field:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Bilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Unilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Or evaluate each affected eye as 20/50 (6/15)</ENT>
                </ROW>
                <ROW>
                  <PRTPAGE P="428"/>
                  <ENT I="22">Concentric contraction of visual field:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03" O="xl">With remaining field of 5 degrees: <SU>1</SU>
                  </ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Bilateral</ENT>
                  <ENT>100</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Unilateral</ENT>
                  <ENT>30</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Or evaluate each affected eye as 5/200 (1.5/60)</ENT>
                </ROW>
                <ROW>
                  <ENT I="22">With remaining field of 6 to 15 degrees:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Bilateral</ENT>
                  <ENT>70</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Unilateral</ENT>
                  <ENT>20</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Or evaluate each affected eye as 20/200 (6/60)</ENT>
                </ROW>
                <ROW>
                  <ENT I="22">With remaining field of 16 to 30 degrees:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Bilateral</ENT>
                  <ENT>50</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Unilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Or evaluate each affected eye as 20/100 (6/30)</ENT>
                </ROW>
                <ROW>
                  <ENT I="22">With remaining field of 31 to 45 degrees:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Bilateral</ENT>
                  <ENT>30</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Unilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Or evaluate each affected eye as 20/70 (6/21)</ENT>
                </ROW>
                <ROW>
                  <ENT I="22">With remaining field of 46 to 60 degrees:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Bilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Unilateral</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Or evaluate each affected eye as 20/50 (6/15)</ENT>
                </ROW>
                <ROW>
                  <ENT I="22">6081 Scotoma, unilateral:</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Minimum, with scotoma affecting at least one-quarter of the visual field (quadrantanopsia) or with centrally located scotoma of any size</ENT>
                  <ENT>10</ENT>
                </ROW>
                <ROW>
                  <ENT I="03">Alternatively, evaluate based on visual impairment due to scotoma, if that would result in a higher evaluation</ENT>
                </ROW>
                <TNOTE>
                  <SU>1</SU> Review for entitlement to special monthly compensation under 38 CFR 3.350.</TNOTE>
